Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 18/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966034 | 0.90 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL4724129 | 0.87 | EGLN2 (0.69) | EGLN2EGLN1 | |
| SCHEMBL1527778 | 0.85 | EGLN2 (0.55) | EGLN2EGLN1 | |
| SCHEMBL522689 | 0.81 | EGLN2 (0.55) | EGLN2EGLN1 | |
| SCHEMBL13601807 | 0.80 | EGLN2 (0.48) | EGLN2EGLN1 | |
| SCHEMBL30401673 | 0.79 | EGLN2 (0.48) | EGLN2EGLN1 | |
| SCHEMBL523424 | 0.78 | EGLN1 (0.78) | EGLN2EGLN1 | |
| SCHEMBL1527732 | 0.77 | EGLN2 (0.56) | EGLN2EGLN1 | |
| SCHEMBL1034273 | 0.76 | EGLN2 (0.52) | EGLN2EGLN1 | |
| SCHEMBL1527650 | 0.76 | EGLN2 (0.48) | EGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | EGLN2 4/4885EGLN1 16/4885SLC1A3 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.